Ascendis Pharma A/S (NASDAQ:ASND) is scheduled to announce its earnings results after the market closes on Wednesday, March 28th. Analysts expect the company to announce earnings of ($0.90) per share for the quarter.
Shares of ASND stock opened at $64.10 on Wednesday. The company has a market capitalization of $2,649.22, a price-to-earnings ratio of -17.31 and a beta of 0.68. Ascendis Pharma A/S has a 1 year low of $21.95 and a 1 year high of $69.00.
A number of equities research analysts have recently commented on the company. Credit Suisse Group reaffirmed an “outperform” rating and issued a $78.00 price objective (up previously from $50.00) on shares of Ascendis Pharma A/S in a research report on Tuesday. Zacks Investment Research raised Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research report on Thursday, March 1st. Wedbush reaffirmed an “outperform” rating and issued a $67.00 price objective on shares of Ascendis Pharma A/S in a research report on Monday, February 26th. Bank of America lifted their price objective on Ascendis Pharma A/S from $45.00 to $60.00 and gave the company a “buy” rating in a research report on Thursday, January 25th. Finally, BidaskClub raised Ascendis Pharma A/S from a “buy” rating to a “strong-buy” rating in a research report on Thursday, January 25th. Three equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $57.33.
Ascendis Pharma A/S Company Profile
Ascendis Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop sustained release prodrug therapies with several product candidates in clinical and preclinical development. The Company is developing its product candidate, TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications.
Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.